Cancer Immunology and Immunotherapy

Ammar Sukari; Misako Nagasaka; Ameer Al-Hadidi; Lawrence G Lum

doi:10.21873/anticanres.11144

Cancer Immunology and Immunotherapy

Anticancer Res. 2016 Nov;36(11):5593-5606. doi: 10.21873/anticanres.11144.

Authors

Ammar Sukari¹, Misako Nagasaka², Ameer Al-Hadidi³, Lawrence G Lum⁴

Affiliations

¹ Karmanos Cancer Institute/Wayne State University School of Medicine, Department of Oncology, Detroit, MI, U.S.A. sukaria@karmanos.org.
² Karmanos Cancer Institute/Wayne State University School of Medicine, Department of Oncology, Detroit, MI, U.S.A.
³ Beaumont Health System, Department of General Surgery, Royal Oak, MI, U.S.A.
⁴ Emily Couric Cancer Center, Hematology/Oncology, Department of Medicine, University of Virginia, Charlottesville, VA, U.S.A.

PMID: 27793882
DOI: 10.21873/anticanres.11144

Abstract

Hanahan and Weinberg described six distinct biological properties of cancer cells that enable tumor growth and metastasis. These properties were referred to as the traditional hallmarks of cancer. Recent discoveries further elucidated hallmarks including evasion of immune destruction by tumor cells that disrupt anticancer response pathways. This review discusses cancer immunology and new treatment strategies aimed at restoration of antitumor immune responses.

Keywords: CTLA4; Cancer immunology; PD1; PDL1; checkpoint inhibitor; immunotherapy.

Publication types

Review

MeSH terms

Humans
Immunotherapy*
Neoplasms / immunology*
Neoplasms / therapy*